About this Project
Their desire to make the best use of funds isn’t motivated by greed. Their commitment is to find solutions to the world’s biggest healthcare challenges. They develop and manufacture life-saving medications for oncology, rare diseases, neuroscience, and gastroenterology. They have facilities in Japan, Switzerland, the United Kingdom, Singapore, and the United States. They contacted InServe MIG to assist at the Major Global Pharmaceutical Company’s site in North America.
The Problem
No Established
Mechanical Integrity Program
This Major Global Pharmaceutical Company completed the construction of and began using its North America site in 2014. They needed to establish a mechanical integrity program to ensure the safety and reliability of what they produced and to provide ongoing risk assessment.
The challenge was starting almost from scratch. This Major Global Pharmaceutical Company had plenty of data, but it wasn’t in a logical, usable format. They needed a better approach to data collection that was easy for them to maintain going forward. They also hadn’t completed any internal or damage mechanism inspections and needed a system for prioritizing what was most critical.
How We Solved It
Implementing Our RBI Program
InServe MIG was able to help this Major Global Pharmaceutical Company save significant amounts of both money and time using our Risk-Based Inspection (RBI) Program. Our process helps organizations identify what inspections are most imperative, so low-risk equipment doesn’t take up more resources than it needs to.
On average, RBI increases inspection intervals by seven years and reduces cost by 30 percent. Find out exactly how we were able to help this Major Global Pharmaceutical Company when you download our case study below.
